News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD) and World Health Organization Establish New Five-Year Initiative to Prevent Deaths from Visceral Leishmaniasis


12/8/2011 7:07:00 AM

GENEVA--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it will donate 445,000 vials of AmBisome® (amphotericin B liposome for injection) over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES